fully automated, sample-to-result molecular diagnostic platform that identifies infectious pathogens and their critical antibiotic resistance genes in under 30 minutes with >99% sensitivity and specificity. Our portable, laptop-sized device combines proprietary nucleic acid amplification with an AI-driven engine to deliver clear, actionable results directly to clinicians, veterinarians, and public health officials.

Our platform is a modular "One Health" solution, adaptable via disease-specific kits for human, veterinary, and environmental applications. We are entering the market with a diagnostic for Urinary Tract Infections (UTIs), a condition affecting over 500 million people annually and a primary driver of antibiotic misuse. By enabling targeted therapy at the first patient encounter, our platform is set to reduce treatment costs by up to 13%, cut follow-up visits, and decrease mortality from complicated infections by 50%.

GeneSys Bio is positioned to capture a significant share of this market by bridging the critical gap between speed, laboratory-grade accuracy, and accessibility. We are not just creating a device; we are building the future of decentralized infectious disease diagnostics to safeguard global health for generations to come